A Study of ALKS 4230 With Pembrolizumab in Head and Neck Cancer
Condition: Non-cutaneous Squamous Cell Carcinoma of Head and Neck Interventions: Drug: ALKS 4230; Drug: Pembrolizumab Sponsors: Alkermes, Inc.; Immune Oncology Network Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer | Cancer & Oncology | Carcinoma | Head and Neck Cancer | Research | Skin Cancer | Squamous Cell Carcinoma | Study